Accéder au contenu
MilliporeSigma

Principaux documents

Voir toute la documentation

901494

N-Methylated pomalidomide

≥98%

Synonyme(s) :

4-Amino-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, E3 Ligase ligand methylated negative control, Ligand for PROTAC® research

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :
C14H13N3O4
Numéro CAS:
1352827-50-9
Poids moléculaire :
287.27
MDL number:
MFCD31703382
UNSPSC Code:
12352101
NACRES:
NA.22
Assay:
≥98%
Form:
powder or crystals
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

ligand

N-Methylated Pomalidomide

Quality Level

100

assay

≥98%

form

powder or crystals

reaction suitability

reagent type: ligand

shipped in

wet ice

storage temp.

2-8°C

SMILES string

O=C(C(CC1)N(C2=O)C(C3=C2C=CC=C3N)=O)N(C)C1=O

InChI

1S/C14H13N3O4/c1-16-10(18)6-5-9(13(16)20)17-12(19)7-3-2-4-8(15)11(7)14(17)21/h2-4,9H,5-6,15H2,1H3

InChI key

YSWQOCGODHPKED-UHFFFAOYSA-N

Application

N-Methylated pomalidomide is a ligand used as a negative control for pomalidomide (P0018) in the recruitment of the Cereblon (CRBN) protein for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.

Other Notes

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Portal: Building PROTAC® Degraders for Targeted Protein Degradation

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Targeted Protein Degradation by Small Molecules

Small-Molecule PROTACS: New Approaches to Protein Degradation

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Articles

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

Jing Lu et al.
Chemistry & biology, 22(6), 755-763 (2015-06-09)
BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathological settings, particularly cancer. While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt's lymphoma (BL), we show that BRD4 inhibitors lead to
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of

Numéro d'article de commerce international

RéférenceGTIN
901494-25MG04061834671558